Aprepitant—licensed for chemotherapy-induced emesis and explored for refractory migraine—induces apoptosis in NK1-R-positive glioma cultures and diminishes Akt phosphorylation in vivo (66, 69, 70). Here, TACR1 is linked to central nervous system cancer.